Targeted cancer therapies can be remarkably effective at shrinking tumors, but they come with a distinct set of drawbacks that sets them apart from older chemotherapy drugs. The most consequential is drug resistance, which develops in the majority of patients and limits how long these treatments work. Beyond resistance, targeted therapies carry their own toxicities, pose challenges with drug interactions, often fail to reach tumors in the brain, and impose steep financial costs that can affect treatment decisions.
Drug Resistance Develops in Most Patients
The single biggest limitation of targeted therapy is that cancers almost always find a way around it. The drugs work by blocking a specific molecular target, usually a protein that drives the cancer’s growth. When the drug succeeds in shutting down that protein, the tumor shrinks, sometimes dramatically. But over time, cancer cells acquire changes that let them grow again despite the drug’s presence.
The most common form of acquired resistance involves new mutations in the gene that the drug targets. In chronic myeloid leukemia, for instance, mutations in the tyrosine kinase domain have historically been the dominant way tumors escape treatment. Similar point mutations have been identified against drugs used in acute myeloid leukemia, chronic lymphocytic leukemia, and lymphoma.1PubMed Central. Secondary mutations as mediators of resistance to targeted therapy in leukemia A detailed classification has identified at least five categories of these on-target mutations, including gatekeeper mutations that physically block the drug from binding, solvent-front mutations, and compound mutations where two changes occur in the same gene.2PubMed Central. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies
Resistance does not always involve changes to the drug’s direct target. Cancer cells can also activate entirely different signaling pathways that keep them alive even while the original target remains suppressed. In lung cancer, for example, several alternative receptor tyrosine kinases have been found to maintain downstream survival signals despite sustained inhibition of the original drug target.3PubMed Central. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer These compensatory loops are sometimes triggered by the drug itself: the initial blockade releases regulatory feedback that had been keeping backup pathways in check. Once that feedback is removed, alternative kinases ramp up and take over the job of promoting tumor growth.4PubMed Central. Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops The practical upshot is that blocking a single molecular target is often not enough to produce a lasting effect.
Tumor Heterogeneity Limits Who Benefits and for How Long
Targeted therapy is built on the idea that a tumor depends on one key molecular driver, but tumors are not genetically uniform. A single tumor mass can contain millions of cells with slightly different genetic profiles. Some of those cells carry the mutation the drug targets. Others do not, or carry it at lower levels.
Research in lung cancer has shown that even within EGFR-mutant tumors, some clones express low levels of the target protein. These EGFR-low cells are inherently more tolerant of EGFR-blocking drugs, more invasive, and display features of a more aggressive cell type compared to their high-expressing counterparts.5PubMed Central. Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment In effect, the drug clears out the sensitive cells while the resistant minority survives, expands, and eventually becomes the dominant population. This progression from “minimal residual disease” to full-blown resistant tumor has been proposed as a general model of how targeted therapy fails: a small subpopulation endures the drug and develops further mutations that let it regrow.6PubMed Central. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
This matters for patients because it means that even a spectacular initial response to a targeted drug does not guarantee durable disease control. The very success of the drug in killing off the majority of tumor cells can set the stage for a more resistant cancer to emerge. Clinicians often talk about the “progression-free survival” window, and for many targeted therapies that window is measured in months rather than years.
Cardiovascular and Metabolic Toxicities
Because targeted therapies are more precise than traditional chemotherapy, early enthusiasm assumed they would also be gentler on the body. That has not consistently been the case. Many of these drugs hit molecular targets that are not exclusive to cancer cells but also play important roles in the heart, blood vessels, and metabolic processes.
Drugs that block the HER2 pathway, widely used in breast cancer, can cause left ventricular dysfunction and even congestive heart failure.7PubMed Central. Targeted therapies in breast cancer: are heart and vessels also being targeted? The mechanism is different from the heart damage caused by older chemotherapy agents like doxorubicin. HER2 inhibitors block a signaling pathway that cardiomyocytes, the cells of the heart muscle, also rely on for survival.8Journal of Cardiovascular Medicine. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors The result is a form of cardiac toxicity that is directly tied to the drug’s intended mechanism, not an off-target accident.
Drugs targeting the VEGF signaling pathway, used to block the growth of new blood vessels that feed tumors, cause high blood pressure in roughly 30 to 80 percent of patients.9PubMed Central. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker This hypertension is an on-target toxicity: it reflects effective blockade of a pathway that is also crucial for maintaining normal vascular function. Beyond elevated blood pressure, VEGF inhibitors are associated with arterial blood clots, generalized endothelial dysfunction, and in more concerning cases, arterial thromboembolic events.10PubMed Central. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events Broader cardiovascular effects including heart failure, arrhythmias, and arterial thrombosis have been documented across drugs targeting HER2, VEGF, and other tyrosine kinases.11PubMed. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review
Metabolic side effects are another concern. Drugs that inhibit the PI3K pathway, used in some breast cancers, can trigger severe hyperglycemia because the PI3K pathway also mediates the action of insulin. Without normal PI3K signaling, insulin cannot effectively drive glucose into cells, resulting in high blood sugar that sometimes reaches the severity of a diabetic crisis.12PubMed Central. Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition Elevated blood lipids have also been reported alongside hyperglycemia in patients on PI3K and mTOR pathway inhibitors.13PubMed Central. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway
Skin Reactions and Everyday Quality of Life
The side-effect profile of targeted therapy is different from chemotherapy, but “different” does not mean “mild.” EGFR inhibitors, a mainstay in lung and colorectal cancers, cause an acne-like skin rash in the majority of patients, with rates reported between 50 and 100 percent depending on the specific drug.14PubMed Central. Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights The rash typically appears on the face, scalp, and upper torso within the first weeks of treatment. For some patients it is cosmetically distressing enough, or physically painful enough, that they reduce or stop their cancer treatment entirely.15PubMed Central. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Diarrhea is another common side effect across several classes of targeted drugs. It can become severe enough to require hospitalization and, like the skin rash, sometimes leads to dose reductions or treatment interruptions that may compromise the therapy’s effectiveness.16PubMed. Targeted therapy-induced diarrhea: A review of the literature These side effects matter not because any single one is necessarily life-threatening, but because they accumulate. A patient dealing with persistent rash, chronic diarrhea, and high blood pressure from their cancer drug faces a daily burden that can erode quality of life even when the tumor itself is responding well.
Drug Interactions Create a Hidden Risk
Many targeted therapies, especially tyrosine kinase inhibitors and mTOR inhibitors, are broken down in the liver by the same enzyme family (cytochrome P450) that metabolizes a wide range of other common medications. This becomes a practical problem because cancer patients are increasingly likely to be older adults managing other chronic conditions with their own medications.
When a blood pressure drug, an antifungal, or even a grapefruit-containing supplement alters the activity of those liver enzymes, the concentration of the targeted therapy in a patient’s blood can swing unpredictably. Too little drug and the cancer cells are inadequately suppressed, potentially favoring the selection of resistant clones. Too much drug and toxicity increases.17PubMed. Drug interactions with solid tumour-targeted therapies Older chemotherapies posed drug interaction risks too, but those were typically administered intravenously in controlled clinical settings. Targeted therapies are often daily oral pills taken at home, where interactions with other prescriptions or supplements are easier to miss.
The Blood-Brain Barrier Keeps Drugs Out of the Brain
Targeted therapies have extended life for many patients with advanced cancers, but in a cruel irony, that extended survival has revealed a new vulnerability. As patients live longer on effective systemic treatment, their brain becomes a refuge for cancer cells. The blood-brain barrier, the tightly sealed network of blood vessels that protects the brain, also blocks many targeted drugs from getting in. Even when a drug is highly effective against tumors elsewhere in the body, tumor cells that have traveled to the brain can persist undisturbed.18PubMed. Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability
The barrier is not uniformly sealed around brain metastases; it can be variably “leaky” in spots. But even these leaky areas often contain active efflux transporters, molecular pumps that actively push drug molecules back out of brain tissue. The result is that while a drug may trickle into part of a brain tumor, it rarely reaches the concentration needed to kill the cancer cells there.19PubMed Central. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine For patients with cancers that commonly spread to the brain, like certain lung and breast cancers, this remains a serious limitation of targeted approaches.
Disease Flare When Treatment Is Paused
Because targeted therapies suppress rather than eliminate cancer cells, stopping the drug, even briefly, can be dangerous. In patients with EGFR-mutant lung cancer who had developed resistance to erlotinib or gefitinib, researchers observed that some patients experienced rapid tumor growth during drug holidays. The idea that taking a break might “reset” the tumor’s sensitivity sounds intuitive, but the data suggest it does not work for everyone and that the break itself can accelerate disease.20Clinical Cancer Research. Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
A similar phenomenon has been documented with ibrutinib in chronic lymphocytic leukemia. Among patients who had their treatment temporarily held, about a quarter experienced a disease flare, including constitutional symptoms and, in some cases, measurable worsening on imaging. All flares resolved when the drug was restarted, but the episode itself can be frightening and medically significant, especially in patients who need to pause treatment for surgery or other procedures.21The Oncologist. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia This dependency on continuous treatment is a genuine burden: patients feel locked into their medication, and any interruption from side effects, insurance gaps, or scheduling issues carries real risk.
Financial Burden and Unequal Access
Targeted therapies are expensive, often running thousands of dollars per month, and the costs are not evenly distributed. Cost-sharing policies have increasingly shifted expenses onto patients, and the resulting financial strain has been linked to poorer quality of life, worse mental health, and lower treatment adherence. In oncology, researchers now use the term “financial toxicity” to describe this phenomenon, recognizing it as a side effect of treatment no less real than nausea or fatigue.22PubMed Central. Financial toxicity and implications for cancer care in the era of molecular and immune therapies
Access to targeted therapy also depends on access to the molecular testing needed to identify which patients are eligible, and that testing is not equally available. A large U.S. study found significant delays in receiving genomic sequencing among Black, Hispanic, and low-income patients across multiple cancer types. In advanced non-small cell lung cancer, Black patients waited roughly 40 percent longer for sequencing results compared to white patients, and patients on Medicare experienced similar delays.23JAMA Network Open. Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States A separate review confirmed that patients with non-small cell lung cancer received less genetic testing and less targeted therapy if they had lower socioeconomic status, public or no insurance, were Black, or lived in rural areas.24PubMed. Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review A drug that works brilliantly when matched to the right tumor is useless if the patient never gets the test that would have identified the match.
Unique Concerns in Children
Most targeted therapies were developed and tested in adults, but pediatric oncologists are increasingly using them in children. The problem is that children are not small adults. They are still developing, and the molecular pathways targeted by these drugs often play roles in normal growth that differ from their roles in mature tissues. Blocking a signaling pathway that merely raises blood pressure in an adult could disrupt bone growth, organ maturation, or hormonal development in a child.25PubMed Central. Targeting developmental pathways in children with cancer: what price success? Because so few targeted agents have been through rigorous pediatric trials, many of these long-term effects remain unknown and may only become apparent years after treatment ends.
Risks When Targeted Drugs Are Used Outside Cancer
Targeted therapies are no longer confined to oncology. JAK inhibitors, originally developed for blood cancers, are now widely prescribed for rheumatoid arthritis, psoriasis, and other inflammatory conditions. Their side-effect profile in this broader population deserves attention. A large pharmacovigilance analysis of over 125,000 reports found that JAK inhibitors were associated with elevated signals for infections, particularly viral (herpes and influenza), fungal, and mycobacterial disorders, as well as musculoskeletal problems, blood clots, and malignant skin tumors.26Scientific Reports. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database For a cancer patient whose alternative is death, those risks look manageable. For someone taking a daily pill for joint pain, the calculus is different, and the decision of whether a targeted therapy’s benefits outweigh its harms becomes more nuanced. These drugs underscore a broader lesson about targeted therapy: precision in mechanism does not automatically translate to precision in safety.